[1] Chen W, Zheng R, Zeng H, et al. The incidence and mortality of major cancers in China [J]. Chin J Cancer, 2016,35(1):73. [2] Blandin S, Crosbie A, Balata H,et al.Progress and pros-pects of early detection in lung cancer [J]. Open Biol, 2017,7(9):170-175. [3] 李为民,赵爽,刘伦旭.肺癌早期诊断方法及临床意义[J].四川大 学学报:医学版,2017,48(3):331-335. [4] Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China [J]. Cancer Lett,2018,30(1):1-12. [5] 赵焕,郭会芹,张传欣,等.纤维支气管镜下刷取标本液基细胞学 检查在肺癌临床诊断中的价值[J].中华肿瘤杂志,2015,37(6): 431-435. [6] 王艺,陈旭昕,徐剑铖,等.129例肺癌患者病理类型与支气管镜下 表现及临床特征的关系分析[J].中国肺部疾病杂志(电子版), 2018,11(2):190-194. [7] 韩仁强,郑荣寿,张思维,等.1989年—2008年中国肺癌发病性 别、城乡差异及平均年龄趋势分析[J].中国肺癌杂志,2013,16 (9):445-451.[8] 林科雄,钱桂生.纤维支气管镜在肺部疾病诊断和治疗中的价值 [J].中华肺部疾病杂志(电子版),2014,7(4):1-3. [9] Friboulet L, Li N, Katayama R,et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non- small cell lung cancer [J]. Cancer discov, 2014,4(6):662-673. [10] Bungay HK, Pal CR, DaVies CW,et al.An evaluation of computed tomorgraphy as an aid to diagnosis in patients undergoing bronchoscopy for suspected bronchial carcinoma [J]. Clin Radiol, 2000,55(5):554-560. [11] 钟巍,王孟昭,陈勇,等.支气管镜在肺癌诊断中的应用[J].癌症进 展杂志,2009,7(3):308-313. [12] Bauman JE, Eaton KD, Wallace SG, et al.A phaseⅡ study of pulse dose imatinib mesylate and weekly paclitax-el in patients aged 70 and over with advanced non-small cell lung cancer [J]. BMC Cancer, 2012,12(1):449. [13] 张丽丽.经电子支气管镜不同取材方法对中央型肺癌的诊断价值 [J].医药前沿,2017,7(23):147-148. [14] 聂华萍,梁伟军,刘胜岗,等.158例青年肺癌患者支气管镜下特征 及临床特点分析[J].肿瘤药学,2016(3):212-216. [15] 赵丽娟,朱辉,王可,等.2670例肺癌支气管镜下表现与病理类型 的关系分析[J].中国呼吸与危重症监护杂志,2009,8(3):287-289.